Can you take a GLP-1 medicine with IBD?
Sometimes, for an appropriate obesity, diabetes or metabolic indication. That is separate from treating bowel inflammation. A retrospective UC study found higher symptomatic remission with liraglutide, sold as Saxenda or Victoza, or semaglutide, sold as Ozempic, Wegovy or Rybelsus. It did not study Crohn's disease or tirzepatide, sold as Mounjaro, and does not establish GLP-1 medicines as IBD treatments.
Patients ask this in two different ways. Some want to know whether they can use Ozempic, Wegovy or Mounjaro when they have IBD. Others have heard these medicines might calm bowel inflammation. Those questions need separate answers.
I am a consultant gastroenterologist, MBBS (London), FRCP (UK), with more than 25 years of clinical experience and nearly two decades of experience in obesity care. That overlap matters because weight, metabolic health, bowel inflammation and nutrition cannot be judged in isolation.
The video focuses on the new ulcerative colitis finding and the proper trials now underway. I mention digestive side effects only briefly in the video. The article below adds practical context about nausea, constipation and diarrhoea because patients with IBD often need help deciding whether a new symptom might be a medicine effect or a change in their bowel disease.
Can GLP-1 medicines be used when you have IBD?
Having Crohn's disease or ulcerative colitis does not automatically rule out a GLP-1 based medicine. The decision depends on the metabolic indication, current IBD activity, nutrition, other medicines and expected side effects.
For simplicity, I use GLP-1 medicines as a broad term on this page. Tirzepatide, sold as Mounjaro, acts on both GIP and GLP-1 receptors.
If semaglutide is prescribed for obesity or diabetes in someone with IBD, the treatment goal is metabolic. Their bowel disease still needs its own treatment and objective monitoring.
What did the 2026 ulcerative colitis study find?
The matched retrospective study used records from one US academic health system. Adults with UC started liraglutide, sold as Saxenda or Victoza, or semaglutide, sold as Ozempic, Wegovy or Rybelsus, for metabolic indications and remained on treatment for at least 12 weeks.
Researchers matched 150 treated patients with 150 controls. At 12 weeks, 66.7% of the treated group met the study's symptomatic remission definition, compared with 25.3% of controls. The adjusted odds ratio was 5.90. Endoscopic data were available only in a subset, and weight loss was not associated with remission.
| Included | Not included |
|---|---|
| Ulcerative colitis | Crohn's disease |
| Liraglutide: Saxenda or Victoza | Tirzepatide or Mounjaro |
| Semaglutide: Ozempic, Wegovy or Rybelsus | A GLP-1 IBD treatment strategy |
| Retrospective matched cohort | Random allocation or blinded placebo comparison |
| 12-week symptomatic remission | Long-term hospitalisation or colectomy outcomes |
Why does the study not prove that GLP-1 medicines treat IBD?
Retrospective studies cannot remove every difference between treated and untreated patients. Treatment choice, clinician contact, diet, other medicines and unmeasured health differences may influence the result.
The primary endpoint was symptom based. Symptoms matter, but they do not always match inflammation. Endoscopic findings came from a subset. Prospective trials with objective inflammation endpoints are needed.
What are the COMMIT-UC and COMMIT-CD trials testing?
These are randomised trials that are now recruiting. They ask a different question from the retrospective UC study.
COMMIT-UC
About 350 adults with moderately to severely active ulcerative colitis and overweight or obesity.
COMMIT-CD
About 290 adults with moderately to severely active Crohn's disease and overweight or obesity.
Both compare mirikizumab, sold as Omvoh, plus tirzepatide, sold as Mounjaro, with mirikizumab plus placebo. Tirzepatide is being added to an IBD biologic. It is not replacing IBD treatment.
The trials will assess bowel-disease outcomes and weight reduction. No results are available yet. They should provide stronger evidence than a look-back study about whether adding tirzepatide changes IBD outcomes.
Can GLP-1 side effects look like an IBD flare?
Yes. Nausea, reduced appetite, abdominal discomfort, constipation, diarrhoea and vomiting can occur with these medicines. Timing can help, but it is not enough. Rectal bleeding, nocturnal symptoms, fever, dehydration or steadily worsening pain need careful assessment.
When the distinction is unclear, the IBD team may use faecal calprotectin, CRP, blood counts, stool testing, imaging or endoscopy.
What should be reviewed before starting one?
The team should understand the metabolic indication, IBD activity, nutritional state and baseline gastrointestinal symptoms. Previous pancreatitis, gallbladder problems, severe delayed stomach emptying, pregnancy plans and the safety profile of the specific medicine may be relevant.
IBD can already affect weight and nutrition. Further appetite suppression or rapid weight loss may be unhelpful when someone is undernourished or losing weight because of active inflammation.
My clinical view
The UC result is encouraging enough to justify better prospective research. It is not enough to make me prescribe semaglutide as an ulcerative colitis treatment.
If a patient has a sound metabolic reason for a GLP-1 medicine, IBD should be part of the planning rather than an automatic barrier. Metabolic treatment and IBD treatment may sit alongside each other. They are not the same treatment goal.
Would you like more evidence-based IBD updates?
Choose Gut Health Dubai as a Preferred Source on Google so future Crohn's disease, ulcerative colitis and treatment updates are easier to find.
Frequently asked questions
Do Ozempic or Wegovy treat ulcerative colitis?
They are not established ulcerative colitis treatments. The retrospective study found an association with symptomatic remission but cannot prove treatment effect.
Was Mounjaro or tirzepatide included in the new study?
No. The retrospective study included liraglutide and semaglutide. Mounjaro is being studied separately in COMMIT-UC and COMMIT-CD, where it is added to mirikizumab rather than used instead of IBD treatment. Those trials do not yet have results.
Can nausea or diarrhoea from a GLP-1 medicine resemble an IBD flare?
Yes. Symptoms overlap. Timing, rectal bleeding and objective inflammation tests may help distinguish them.
Should established IBD treatment be stopped when starting a GLP-1 medicine?
No treatment should be stopped or changed without the IBD team. A GLP-1 medicine for a metabolic indication is not a substitute for IBD treatment.
Research sources
Alqinai, Gayam and Hadam-Veverka, Inflammatory Bowel Diseases, DOI 10.1093/ibd/izag167
COMMIT-UC, ClinicalTrials.gov NCT06937086
COMMIT-CD, ClinicalTrials.gov NCT06937099
This article is for general education and does not replace individual medical advice. Do not start, stop or change a GLP-1 medicine or an IBD treatment without discussing it with the clinicians responsible for your care.
Recommended related reading
If you would like to discuss how a metabolic medicine fits alongside your IBD care, you can use the appointment form below.